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ABSTRACT  
 
Marbofloxacin is a fluoroquinolone with a wide spectrum of activity. This spectrum includes 
Actinobacillus pleuroneumoniae (APP) that is the causative agent of porcine pleuroneumonia. APP 
can remain in the tonsils of asymptomatic pigs for a long period maintaining the disease in the herd. 
The penetration of marbofloxacin into tonsils was assessed in fattening pigs. Two different dosages 
were used to treat the animals: 2 mg/kg b.w. every 24 hours during 3 days (P1 group) and 4 mg/kg 
b.w. every 48 hours two times (P2 group). Marbofloxacin achieved a mean concentration in tonsils 
of 0.5 and 0.7 µg/mL 24 hours after the last administration in groups P1 and P2, respectively. 
Marbofloxacin achieved a tonsillar concentration three times greater than the plasma concentration 
whatever the dose administered 24 hours after the last administration. A ratio between the mean 
tonsillar concentration of marbofloxacin for both doses (0.5 and 0.7 µgr/mL) and its MIC90 for APP 
(0.03 g/mL) was calculated. These Ratio values were 16.6 and 23.3 for P1 and P2 group, 
respectively and were also above the threshold established for PK/PD efficacy parameters in the 
case of fluoroquinolones.  These findings suggest that marbofloxacin could be a good candidate to 
carry out additional studies focused on deciphering the potential use of this antibiotic for control or 
eradication programs in APP affected farms.  
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1. INTRODUCTION 
 
QUINOLONES 
Quinolones belong to a large and expanding group of synthetic antimicrobial agents. This group of 
antibiotics began with the discovery of the nalidixic acid in 1962 as a by-product of anti-malarial 
research in 1962 (Lesher et al., 1962).  The nalixidic acid (figure 1) had a good activity against 
aerobic Gram negative, but reached solely the therapeutic concentration in urine. Owing to this 
particularity, the nalixidic acid was used for the treatment of urinary tract infections. The addition 
of a fluorine atom at the 6 position on the quinolone carboxylic acid nucleus enhanced the efficacy 
of the quinolones against gram negative pathogens and broadened the spectrum of activity against 
Gram positive pathogens. Moreover, the addition of piperazine derivatives in the 7-position 
enhanced tissue penetration and it also reduced its central nervous system toxicity. As a result of 
these improvements a second generation of drugs were born, the fluoroquinolones (FQ) (M. 
Martinez et al., 2006). 
 
Figure 1. Nalidixic acid. Martinez et al. (2006) 
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FLUOROQUINOLONES 
The FQ have a good oral absorption (exceptions: ruminants and horses), complete parenteral 
absorption, and good tissue distribution owing to their physicochemical properties. Their 
metabolism and excretion occurs in the liver and in the kidney, respectively. These antimicrobials 
have a wide spectrum of action against gram-negative bacteria, mycoplasma and some gram 
positive bacteria.  FQ affect the DNA supercoiling by inhibit an enzyme found in all bacteria, the 
DNA gyrase. This gyrase plays a vital role in DNA packing, replication and transcription. 
Furthermore, the FQ have a secondary target, the topoisomerase IV that acts in the ATP dependent 
relaxation of the DNA (M. Martinez et al., 2006). There are some FQ only used in animals 
(enrofloxacin, difloxacin, danofloxacin, marbofloxacin, orbifloxacin and sarafloxacin) (figure 2). 
 
 
Figure 2. Chemical structures of different fluoroquinolones. Martínez et al. (2006) 
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MARBOFLOXACIN 
Marbofloxacin (MB) (figure 3) is a fluoroquinolone widely used in veterinary medicine. This 
molecule is an organic acid with good tissue penetration. Its volume of distribution exceeds the 
body water volume and the degree of binding to plasma proteins is low (Sidhu et al., 2009).  It 
possesses a broad spectrum of activity against mycoplasma, most Gram negative, some Gram 
positive bacteria and some intracellular pathogens such as Brucella and Chlamydia species, but 
with limited or no activity against anaerobes (Hannan et al., 1989; Spreng et al., 1995; Appelbaum 
and Hunter, 2000). This spectrum of activity includes most of the swine respiratory pathogens, 
including Actinobacillus pleuropneumoniae (APP).  
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Figure 3. Chemical structure of Marbofloxacin. (Kindly provided by Vetoquinol International) 
 
PORCINE RESPIRATORY DISEASE COMPLEX 
Porcine respiratory disease complex (PRDC) is clinically characterized by dyspnoea, coughing, 
acute depression, anorexia, fever, and nasal discharge, specially affecting growing to finishing pigs 
(Dee, 1996). This complex disease is most often due to the interaction of multiple factors. Both 
viral and bacterial organisms play a role, as well as the environment and various management 
practices employed by producers. When in the right combination, these factors can sufficiently 
compromise the pig respiratory defense mechanisms, resulting in severe respiratory disease 
(Thacker et al., 2006). The most common viral pathogens associated with PRDC are porcine 
respiratory and reproductive syndrome virus (PRRSV), swine influenza virus (SIV), pseudorabies 
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virus (PRV) and porcine respiratory coronavirus (PRCV). The most common bacterial pathogens 
associated with this complex include: Mycoplasma hyopneumoniae, Actinobacillus 
pleuropneumoniae, Bordetella bronchiseptica, Pasteurella multocida, Haemophilus parasuis, 
Streptococcus suis, Arcanobacterium pyogenes, Salmonella choleraesuis and Actinobacillus suis 
(Christensen et al., 1999). 
 
PLEUROPNEUMONIA 
APP is the causative agent of porcine pleuropneumonia,
 
a worldwide disease with occasional 
clinical outbreaks that can
 
have a severe economic impact (Gottschalk and Taylor, 2006). Attempts 
to control the disease have been made by
 
vaccination, treatment with antibiotics and the 
establishment
 
of herds free of the infection. Pigs can become asymptomatic carriers of
 
the organism 
in their tonsils for long periods (Macinnes and Rosendahl, 1988; Vigre et al., 2002), thereby
 
exposing susceptible animals and maintaining the disease in
 
the herd. Moreover, pigs can carry APP 
in their tonsils
 
for several months without seroconverting (Lavritsen et al., 2002). 
Attempts to eradicate APP from pig herds have
 
been made with different antibiotics. For example, 
Fittipaldi et al. (2005) used
 
feed medicated with tilmicosin phosphate for 30 days but found
 
that the 
tonsils of the majority of animals were still PCR-positive
 
30 days later. Most of the results have 
been published in case
 
reports describing procedures applied to one or a few farms (Angen et al., 
2008). On the other hand, an eradication program that includes sow medication with a 
fluorquinolone was successful (Bækbo, 2006). However, these field trials are not supported with the 
determination of antibiotic concentration in the tonsils (target tissue).  
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PK/PD RELATIONSHIP 
The pharmacokinetics describes, through mathematic concepts, the kinetics of a drug inside the 
organism and defines a pattern of the ADME process (Absorption, Distribution, Metabolism and 
Elimination) of each drug. The most relevant pharmacokinetic parameters (Cmax, tmax, AUC, 
bioavailability, volume of distribution at steady-state, and elimination half-lives) have been 
described for many antimicrobial drugs in several species of veterinary interest. These parameters 
are necessary to establish the posology regimen for each particular species. 
One of the most important PK considerations is where to measure drug concentrations from which 
PK data are derived. It is evident that the antimicrobial should reach the locus of the offending 
bacteria to be effective and, therefore, it could be assumed that tissue or cellular concentrations 
would be the most appropriate for determining the required kinetic parameters (McKellar et al., 
2004). Nevertheless, plasma concentrations have been shown to be the best predictors of clinic 
success even for most tissue infections (Schentag, 1989; Toutain et al., 2004). Otherwise, there are 
special cases, where a specific anatomical or pathological barrier exists, where it may be more 
appropriate to use concentrations derived from that site (Toutain et al., 2004).  
 
Pharmacodynamics studies the action of drugs on microorganisms or on specific receptors in the 
body to modify a physiological action. One of the difference between PD studies on mammalian 
cells/ tissues and on microbes is that the response in the former system is normally quantified as an 
enhancement or reduction of some component of cell or body function (smooth muscle contraction, 
decrease in body temperature, etc.), whereas pharmacodynamics parameters for microorganism 
establish threshold values (MIC or MBC) to link the concentration of antibiotic, normally measured 
in serum or plasma, with the growth of the microorganism population. The most widely used in 
vitro PD parameter is the minimum inhibitory concentration (MIC). This parameter is determined 
under standard culture conditions either on a solid agar medium or, more usually, in liquid broth 
culture. It is defined as the lowest concentration of antimicrobial drug which prevents (as assessed 
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by visual examination) visible microorganism growth. MIC is a simple, versatile, readily performed 
measure, which enables large numbers of microorganisms to be screened. Because MIC varies 
considerably between strains of a single organism, it is usual practice to measure MIC on many (up 
to several hundred) isolates and then compute the MIC50 and MIC90 values. To register an active 
ingredient for antimicrobial use, it is usual to use MIC90 rather than MIC100 values as the main 
pharmacodynamic parameter to establish its posology regimen. This is because, for any given 
population of microorganisms, there will commonly be a small percentage of isolates which are not 
susceptible, even to very high drug concentrations. MIC90 provides the best available indicator to 
link with PK data and establish a posology regimen to be applied under field conditions (Lees et al., 
2004). It is important to take into account that the distribution of MICs in a wide range of isolates is 
not always normally distributed (Alibadi et al., 2000). 
 
The utility of PK/PD information is demonstrable in the development of new antimicrobials, the 
more specific selection of appropriate antimicrobials from formularies, the design of optimal dosage 
strategies and the reduction of the selection of antimicrobial resistance (Gunderson et al., 2001). 
 The PK/PD parameters which have been mostly investigated, and for which the most robust 
information is currently available, are AUC0-24:MIC, Cmax:MIC and T>MIC (Hyatt et al., 1995). 
Antimicrobial drugs have been classified as concentration-dependent where increasing 
concentrations at the locus of infection improve bacterial kill, or time-dependent where exceeding 
the MIC for a prolonged percentage of the inter-dosing interval correlates with improved efficacy. 
For the latter group, increasing the absolute concentration obtained above a threshold does not 
improve efficacy. The PK/PD relationship for each group of antimicrobial drugs is “bug and drug” 
specific, although ratios of 125 for AUC0-24:MIC and 10 for Cmax:MIC have been recommended to 
achieve high efficacy for concentration-dependent antimicrobial drugs, and exceeding MIC by 1-5 
multiples for between 40 and 100% of the inter-dosing interval is appropriate for most time-
dependent agents (McKellar et al., 2004).  
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Concentration-dependent Time-dependent Co-dependent 
Aminoglycosides 
Fluoroquinolones 
Metronidazole 
(vs. Anaerobes) 
Beta-lactams 
Macrolides (except azithromycin) 
Clindamycin 
Vancomycin 
Beta-lactams
*
 
Fluoroquinolones
** 
Glycopeptides 
Table 1. General classification of antimicrobial drugs for which information is available on 
concentration or time-dependent killing activity (*In relation to reduction in resistance selection 
pressure;**Some with anaerobic activity). McKellar et al., 2004. 
 
PALATINE TONSIL 
The Palatine Tonsil (PT) is the major immunological component of the oropharinx ubicated in the 
soft palate. This consists of organized lymphoid tissue covered by stratified squamous epithelium 
but penetrated by branching crypts covered with nonkeratinized epithelium. The organized tissue 
contains B cell follicles and T cells (Pastoret et al., 1998). The crypt epithelium is a 
lymphoepithelium containing goblet cells, microfold cells (M cells) and intraepithelial lymphoid 
cells (Belz and Heath, 1996). Some bacteria native to the oropharynx may inhabit the tonsils, 
resulting in subclinical carriers of, for example, Actinobacillus Pleuroneumoniae (Macinnes and 
Rosendahl, 1988; Vigre et al., 2002), Erysipelothrix rhusiopathiae (Takahashi et al., 1999), 
salmonellae, or some groups of streptococci (Pastoret et al., 1998). 
 
 
Taking into account the previous information provided in the introduction, the goal of this study 
was to quantify the marbofloxacin (MB) penetration in tonsils after applying two different MB 
dose regimens to decipher the potential use of this antibiotic for control or eradication programs 
in APP affected farms. 
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2. MATERIALS AND METHODS  
 
ANIMAL SAMPLING. 
Thirty 2-month-old pigs weighting 17.4 to 27 kg were selected for this study coming from a farm 
with clinical cases of porcine pleuropneumonia. Animals were clinically healthy when the study 
began. All pigs included in the study received non-medicated commercial feed ad libitum and had 
free access to drinking water. Animals were randomly divided into three groups (control, P1 and 
P2) of ten animals. All the animals were weighed with a calibrated scale to guarantee an exact dose 
of marbofloxacin or saline and tagged on the ear in order to identify them (table 2). Each treatment 
group received Marbocyl® 2% applied at a dose of 2 mg MB/kg b.w. for three consecutive days 
(group P1) and at a dose of 4 mg MB/kg b.w. every 48 hours two times (group P2) intramuscularly.  
Animals of the control group were sham injected with the same volume of physiological saline 
(2cc). The animals were sacrificed by intravenous administration of pentobarbital sodium twenty 
four hours after the last administration. This sampling time was chosen to allow achieving 
distribution equilibrium in the tonsils even if this tissue would behave as a deep tissue in 
comparison with well-irrigated organs such as the lung. Blood sample were taken to obtain serum 
before the administration of pentobarbital. Tonsils were collected during the necropsy and frozen 
immediately with carbonic ice at -80ºC until analysis. 
 
LABORATORY PROCEDURES 
The concentration of marbofloxacin in serum and tonsils was quantified by HPLC according to 
standard procedures in Vetoquinol laboratories in Lure (France). This extraction method is based on 
a liquid-liquid process with chloroform. Ofloxacin was used as an internal standard. Ofloxacin is a 
molecule that posses a molecular structure similar to marbofloxacin but it has different molecular 
weight. These characteristics are shown in figure 4. 
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Control Group Group P1 
(2mg/Kg) 
Group P2 
(4mg/Kg) 
Animal Weight 
(Kg) 
Dosage 
(cc) 
Animal Weight 
(Kg) 
Dosage 
(cc) 
Animal Weight 
(Kg) 
Dosage 
(cc) 
1 24.5 2 11 23.7 2.37 21 19.2 3.84 
2 25.4 2 12 23.1 2.31 22 26 5.2 
3 23.1 2 13 27 2.7 23 24.6 4.92 
4 24.9 2 14 25.7 2.57 24 24.1 4.82 
5 25.2 2 15 25.5 2.55 25 25.7 5.14 
6 25.3 2 16 23.9 2.4 26 24.6 4.9 
7 23.1 2 17 22.6 2.3 27 20.6 4.1 
8 18.8 2 18 17.4 1.75 28 26.2 5.2 
9 22.9 2 19 23.3 2.3 29 18.5 3.7 
10 25.1 2 20 17.8 1.8 30 18 3.6 
Table 2. Weight and administered volume of saline (control group) and marbofloxacin (P1 and P2 
group). 
 
MARBOFLOXACIN OFLOXACIN 
Empirical formula: C17H19FN4O4 Empirical formula: C18H20FN3O4 
Molecular weight: 362.4 Molecular weight: 361.4 
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Figure 4. Main similarities and differences between marbofloxacin and ofloxacin. Vetoquinol 
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The next solvents and reagents were used to prepare the different solutions needed in the extraction 
procedure: Acetonitrile, acetic acid, ortophosphoric acid, chloroform, potassium dihydrogen 
phosphate, di-ammonium hydrogen phosphate, di-sodium hydrogen phosphate, methanol, 
tetrabutylammonium hydrogen sulphate, triethylamine and ultra-pure water (Milli-Q Millipore). 
Thus, reference substances marbofloxacin and ofloxacin (Sigma). 
Further details of solutions and equipment used are shown in Annex 1. 
 
After thawing the tonsils, 500 mg of porcine tonsil sample were weighted and treated with 1 mL of 
enzymatic solution (protease). The mixture was agitated moderately during 90 min at about 60ºC. 
After cooling, 50 µL of internal standard solution IS2 (Ofloxacin at 1µg/mL) was added, except for 
the blank porcine tonsil and mixed. The samples were adjusted to pH 7 with buffer solution pH 2 
HCl – Citrate (about 300 µL) and 4 mL of chloroform. After the agitation (10 min on a 
reciprocating agitator) and centrifugation (at 5000 rpm for 10 min at about 5ºC), the organic phase 
was transferred in a conical-bottomed inactinic glass tube and evaporated under a nitrogen stream at 
about 38ºC. The dry extract was solved with 200 µL of mobile phase A, mixtured on the vortex, 
sonicated in an ultrasonic bath and mixture on vortex again. The mixture was transferred in an 
Eppendorf tube, it was added 1mL of hexane, mixtured on the vortex and sonicated in an ultrasonic 
bath. Finally, the mixture was centrifugated (1300 rpm for 10 min at about 5ºC) and the bottom 
phase was transferred in vial for injection. 
Calibration samples from 0 to 5 µg/g or 5 µg/mL were prepared with 500 mg of porcine tonsil or 1 
mL of serum (see table  3 below), respectively in order to obtain: 
- 8 samples of blank porcine tonsil or serum with different amounts of marbofloxacin. 
- a blank porcine tonsil or serum with internal standard. 
- a blank porcine tonsil and serum. 
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Marbofloxacin 
concentration of the 
calibration samples 
(µg/g) 
Weight of tonsil 
(mg) 
Used 
marbofloxacin 
standard solution 
Spiking volume 
(µL) 
0 500 NA NA 
0.005 500 A4 25 
0.01 500 A4 50 
0.025 500 A4 125 
0.05 500 A3 25 
0.1 500 A3 50 
1 500 A2 50 
2.5 500 A2 125 
5 500 A1 25 
 
Table 3.  
NA : Not applicable 
 
Briefly, serum samples were extracted with chloroform after adding ofloxacin as internal standard, 
following the same method as described previously from the tonsils. 
 
 
The limit of quantification was 0.005 g/mL for serum and 0.005 g/gr for tonsil. To prepare 
standards, control serum and tonsils from animals which had received no treatment were spiked 
with marbofloxacin, the spiked standard concentrations ranging from 0.005 to 5 μg mL−1 or μg/g.  
Both methods were highly linear with coefficients of correlation of the standard curves (r) better 
than 0.99. Accuracy and reproducibility were determined from inter-day and intra-day variances of 
assays with spiked concentrations. For the serum samples, accuracy was within the range of 100 to 
102 % and precision was better than 5 %. For tonsil samples, accuracy was within the range of 95 to 
103 % and precision was better than 11 %.  
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HPLC-reversed phase with a C18 stationary phase (analytical column: Merck Lichrospher 100RP18 
(250 x 4) mm. 5µm) with fluorescence detection set to 295 nm for excitation and 500 nm for 
emission was used. The mobile phase was a mixture of phosphate buffer (pH 2.7), methanol, 
acetonitrile, acetic acid and triethylamine (86.5/10/2.5/1/0.3 v/v/v/v/v). The method is linear from 
0.005 to 5 µg/g with a weighting factor of 1/C
2
. 
 
The ratio between MB concentration in tonsils and MIC90 value (0.03 g/mL) was calculated to 
obtain a PK/PD parameter as previously described (Mckellar et al., 2004). Moreover, MIC90 for 
APP was determined following CLSI (CLSI M31-A2. 2002) recommendations (Valle et al., 2006). 
The MB tonsil concentration: MIC90 ratio calculated did not correspond to the Cmax/MIC ratio due 
to that the sample time chosen was 24 hours after the intramuscular administration and the Tmax 
described for pigs after intramuscular administration is 0.8 hours (Anonym, 1997). This ratio of 
tissue concentrations versus MIC90 values is one of the PK/PD efficacy parameters described for 
fluoroquinolones (Sarasola et al., 2002).  
 
STATISTICAL ANALYSIS 
A non-parametric test (Mann-Whitney) was used to compare the marbofloxacin concentration 
achieved in serum and tonsils between the P1 and P2 groups. The SPSS 15.0 software was used 
(SPSS Inc., Chicago, IL, USA) to carry out this statistical analysis and the level of significance (α) 
was set to P < 0.05. 
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3. RESULTS 
 
The results of the quantification of marbofloxacin in serum and tonsils are showed in the following 
table: 
Control Group Group P1 Group P2 
Animal Serum 
(µg/mL)  
Tonsils 
(µg/g) 
Animal Serum 
(µg/mL)  
Tonsils 
(µg/g) 
Animal Serum 
(µg/mL)  
Tonsils 
(µg/g) 
1 ND ND 11 0.1988 0.5872 21 0.3394 1.020 
2 ND ND 12 0.1745 0.5399 22 0.1612 0.4693 
3 ND ND 13 0.1797 0.5599 23 0.1876 0.6751 
4 ND ND 14 0.1702 0.5436 24 0.3144 0.9843 
5 ND ND 15 0.1611 0.5691 25 0.1366 0.4270 
6 ND ND 16 0.1235 0.3374 26 0.2533 0.7178 
7 ND ND 17 0.2080 0.6353 27 0.2906 0.7965 
8 ND ND 18 0.1752 0.5212 28 0.2369 0.6745 
9 ND ND 19 0.1230 0.3576 29 0.2285 0.6179 
10 ND ND 20 0.1499 0.3973 30 0.2285 0.6609 
Table 4. Results of quantification of marbofloxacin in serum and tonsils (ND: Under the limit of 
detection). 
 
Average marbofloxacin serum concentration was 0.16 and 0.24 g/mL. 24 hours after administering 
the last Marbocyl® 2% dose for the P1 and P2 group, respectively. Moreover, average 
marbofloxacin tonsil concentration was 0.50 and 0.70 g/gr for the P1 and P2 group, respectively 
(figure 5).  Marbofloxacin concentration were significantly higher for the P2 group than for the P1 
group in plasma (p=0.01) and tonsils (p=0.009). Thus, serum and tonsil tissue concentrations 
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increased in a dose-dependent fashion but the tonsil MB versus serum MB concentration ratio was 
close to 3 independent of the dose administered to the animals. The MB tonsil concentration: APP 
MIC90 ratio was 16.6 and 23.3 for P1 and P2 group, respectively. 
 
 
Figure 5. Mean (+ standard deviation) concentration (g/mL or g/gr. respectively) of 
marbofloxacin (MB) in serum (white bars) and tonsil (grey bars) 24 hours after the last 
intramuscular application of marbofloxacin at 2 and 4 mg of MB/Kg administered three times 
(every 24 hours) and two times (every 48 hours)  respectively in 10 pigs for experimental group. 
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4. DISCUSSION  
 
The main goal of this study was to quantify the penetration of marbofloxacin in pig tonsils. It would 
have been ideal to define its pharmacokinetic tonsil profile using, at least, five sample times as it 
has been described for moxifloxacin in humans (Esposito et al., 2006). However, the quantification 
of this antibiotic in tonsil require to use the complete tonsil and, consequently, to sacrifice the 
animals. Thus, it was decided to use a representative number of animals (10) in one single sample 
time to minimize the number of animals used for welfare reasons. The sample time (24 hours after 
intramuscular administration) was chosen to allow the distribution equilibrium even whether the 
tonsil would behave as a deep tissue for antibiotic penetration in pigs. 
The presented data indicates that MB achieves a good penetration into tonsillar
 
tissue, which is 
comparable with tonsil/plasma
 
ratios reported for other fluoroquinolones such as the ratio of
 
1.5–1.9 
for ciprofloxacin, from 1 to 8 h after oral or
 
intravenous doses of 200–500 mg; 2.02–2.08 for 
levofloxacin,
 
from 1 to 9 h after single oral doses of 100 or 200 mg; and
 
1.4 for ofloxacin, 2 h after 
a single administration of an oral
 
200 mg dose (Fish and Chow, 1997; Falser et al.,1988). 
Tonsil/plasma ratio observed for MB was also very similar to that of moxifloxacin in humans as 
described by Esposito et al. (2006). MB tissue/plasma ratio, for other pig tissues at steady state (4 
hours after a intramuscular dose of 2 mg of MB/body weight), such as the lung (1.8), liver (1.9), 
kidney (3.8), muscle (1.7) and skin (1), is equal or lower than the value observed for pig tonsils 
(Anonymus, 1997) clearly showing that tonsil did show a similar distribution pattern compared to 
most studied pig tissues. 
In all the available bibliography, the tonsil concentration was measured taking into account the 
whole tissue as it was carried out in this study. Obviously, it would have been necessary to measure 
the concentration of unbound drug (marbofloxacin in this case) in the tonsil crypts because the 
determination of drug concentration derived from tissue homogenates could lead to an incorrect 
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conclusion, overestimating or underestimating, the amount of unbound drug in the site of action  
(Mouton et al., 2008). Unfortunately, it is almost impossible to describe the pharmacokinetics of 
this molecule in this target tissue. Thus, the only practical approach was analyzing marbofloxacin in 
the tonsil as a whole. On the other hand, this molecule is an organic acid with good tissue 
penetration and its volume of distribution exceeds the body water volume and the degree of binding 
to plasma proteins is low (Sidhu et al., 2009). All in all, it could be reasonably assumed that the 
concentration at tonsil crypts could be very close to the concentration present in the whole tonsil. 
 
In PK/PD relationships for fluoroquinolones, the Cmax:MIC ratio has been shown to have particular 
utility in determining optimal activity against Gram negative microorganisms (Drusano et al., 1993; 
Sarasola et al., 2002). A Cmax:MIC ratio of >8 and an AUC0--24:MIC ratio of >100 have been 
recommended to prevent resistance selection (Dudley, 1991; Thomas et al., 2001). The MB 
tonsil:MIC ratio described is above the threshold value (10) that is associated with clinical efficacy 
for all the doses studied (Drusano et al,. 1993; Sidhu et al,. 2009). According to the results it could 
be theoretically possible to eliminate Actinobacillus pleuroneumoniae from pig tonsils. Obviously, 
these threshold values have been established taking into account PK/PD parameters calculated from 
serum concentration values and pharmacodynamic parameters estimated using in vitro systems in 
different murine and veterinary models focus on different clinical end-points (for example 
pneumonia resolution). Moreover, it is assumed that the MIC90 value used to estimate PK/PD 
parameters is close to the MIC value that really has Actinobacillus pleuropneumoniae when it is 
located in the tonsil crypts of carrier animals. All in all, it can be discussed that the PK/PD 
parameters calculated are highly speculative and that there is no well-sustained information to be 
used as a reference. Authors might agree with this observation but it must be highlighted that there 
is neither specific PK/PD parameters to be used at tonsil level nor additional information in the 
public domain about pharmacodynamic parameters of this bacteria taking into account different 
biological forms. ThusIn conclusion, the PK/PD values described in this research paper must be 
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considered as the most reasonable approach at this stage. In any case, the information provided here 
should be confirmed by studies whose main goal should be focused on the bacteriological detection 
of APP in the tonsils of animals either by bacteriological isolation or by PCR confirmation.   
 
FUTURE WORK 
To our knowledge, this is the first study that describes the penetration of a fluoroquinolone in the 
pig tonsils. According to the results it could be theoretically possible to eliminate Actinobacillus 
pleuroneumoniae from pig tonsils. Some field studies (Miquel Colell, personal communication) 
have shown that the application of marbofloxacin (4 mg/Kg) every 48 hours two times in the whole 
farm (sows and piglets) reduces the mortality and the symptoms related to APP during the fattening 
period in farms suffering APP outbreaks during an unknown period of time (months or years). 
However, the disease could appear again in the fattening after this period of time after applying a 
marbofloxacin treatment as it has been observed by other authors (Marcelo Gottschalk, personal 
communication). More studies are required to confirm whether this decrease in the mortality would 
be the consequence of theoretical eradication APP or due to the reduction of the bacterial load in 
tonsil that could modify the transmission pattern of this bacterium at population level. 
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I. SOLVENTS AND REAGENTS  
 
1.1 Commercially available solvents and reagents 
Unless specified for each particular product. all solvents and reagents were purchased from 
Sigma –Aldrich, France.  
- Acetonitrile for HPLC 
- Acetic acid 100% (CH3COOH), for analysis 
- Orthophosphoric acid 85% (H3PO4), for analysis 
- Chloroform for analysis 
- Potassium dihydrogen phosphate (KH2PO4) for analysis 
- Di-ammonium hydrogen phosphate ((NH4)2HPO4) for analysis 
- Di-sodium hydrogen phosphate (Na2HPO4. 2H2O) for analysis 
- Methanol for HPLC 
- Tetrabutylammonium hydrogen sulfate (TBA) for analysis 
- Triethylamine (TEA) for analysis 
- Water, ultra-pure.,Milli-Q Millipore, Billerica, MA, USA. 
 
1.2 Reference substances 
 
- Marbofloxacin, Vetoquinol R+D Department, Lure, France. 
- Ofloxacin. 
 
1.3 Prepared solution 
 
1.3.1 Buffer solution pH 7.0 
 
3.538 g of KH2PO4 and 7.3 g of Na2HPO4 (2H2O) were dissolved in about 900 mL of ultra-pure 
water. The volume of the solution was adjusted to 1000 mL with ultra-pure water in a volumetric 
flask. The pH was checked. 
 
1.3.2  Buffer solution pH 2.7 
 
4 g of (NH4)2HPO4 and 4 g of TBA were dissolved in about 900 mL of ultra-pure water. The pH is 
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adjusted to 2.7 with H3PO4. The volume of the solution was adjusted to 1000 mL with ultra-pure 
water in a volumetric flask. The pH was checked daily before use. 
 
1.3.3 Mobile phases 
- Mobile phase  A 
865 mL of buffer solution pH 2.7. 100 mL of methanol. 25 mL of acetonitrile. 10 mL of acetic acid 
and 2.8 mL of TEA were mixed and then degassed by vacuum filtration and ultrasonic bath. 
 
-Mobile phase  B 
About 500 mL of methanol were degassed by vacuum filtration and ultrasonic bath. 
 
1.3.4 Buffer solution pH 9.3 
50 mL of NaOH at 0.1N were measured in a 100 mL volumetric flask. The volume of the solution 
was adjusted to 100 mL with ultra-pure water. The pH was adjusted to 9.3 with heated boric acid. 
 
1.3.5 Enzymatic solution  
The volume prepared depends on the number of samples. 
10 mg of protease were dissolved with 10 mL of buffer solution pH 9.3 
 
1.3.6 Marbofloxacin standard solutions  
Solutions were prepared in volumetric inactinic glass flasks. 
 
- Solution A1: accurately weighed 10 mg of marbofloxacin were dissolved in about 80 mL of 
buffer solution pH 7.0 contained in a 100 mL volumetric inactinic glass flask. The volume was 
completed to 100 mL with buffer solution pH 7.0.  
 Obtained concentration: 100 µg/mL 
 
- Solution A2: accurately measured 5 mL of solution A1 in a 50 mL volumetric inactinic glass 
flask. The volume was completed to 50 mL with buffer solution pH 7.0.  
Obtained concentration: 10 µg/mL 
 
- Solution A3: accurately measured 5 mL of solution A2 in a 50 mL volumetric inactinic glass 
flask. The volume was completed to 50 mL with buffer solution pH 7.0. 
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Obtained concentration: 1 µg/mL 
 
- Solution A4:  accurately measured 5 mL of solution A3 in a 50 mL volumetric inactinic glass 
flask. The volume was completed to 50 mL with buffer solution pH 7.0.  
Obtained concentration: 0.1 µg/mL 
 
1.3.7  Internal standard solutions 
Solutions were prepared in volumetric inactinic glass flasks. 
 
- Solution ISm: accurately weighed 10 mg of ofloxacin were dissolved in about 80 mL of buffer 
solution   pH 7.0 contained in a 100 mL volumetric inactinic glass flask. The volume was 
completed to 100 mL with buffer solution pH 7.0.   
Obtained concentration: 100 µg/mL 
 
- Solution IS1: accurately measured 5 mL of solution ISm in a 50 mL volumetric inactinic glass 
flask. The volume was completed to 50 mL with buffer solution pH 7.0.  
Obtained concentration: 10 µg/mL 
 
- Solution IS2: accurately measured 5 mL of solution IS1 in a 50 mL volumetric inactinic glass 
flask. The volume was completed to 50 mL with buffer solution pH 7.0   
Obtained concentration: 1 µg/mL 
 
1.3.8 Standard solution at 1 µg/mL of marbofloxacin and at 0.2 µg/mL of internal standard in 
mobile phase 
 
Accurately measured 5 mL of solution A2 (10 µg/mL) and 10 mL of solution IS2 (1 µg/mL) were 
mixed in a 50 mL volumetric inactinic glass flask. The volume was completed to 50 mL with 
mobile phase A. 
 
1.4 Stability of the standard solutions  
 
The standard solutions of marbofloxacin at 100 µg/mL and at 0.1 µg/mL and of ofloxacin at 
1µg/mL were stable for 6 hours when they were kept at ambient temperature. 
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The standard solutions of marbofloxacin at 100 µg/mL and the standard solution of ofloxacin at 
1µg/mL were stable for 6 weeks when they were stored at about +4°C   
Consequently, the standard solutions of ofloxacin at 100 and 10 µg/mL could be considered as 
stable for 6 weeks when they were stored at about +4°C. 
The standard solution of marbofloxacin at 0.1 µg/mL was stable for 4 weeks when it was stored at 
about +4°C.  
Consequently, the standard solutions of marbofloxacin at 10 and 1 µg/mL could be considered as 
stable for 4 weeks when they were stored at about +4°C. 
 
II. EQUIPMENT 
 
The small equipment and instrumentation types and trademarks are detailed below: 
 
2.1 Glassware and small equipment  
 
2.1.1 Glassware 
 
- Volumetric glass flasks, Class A, 1000 mL 
- Volumetric inactinic glass flasks, Class A, 50 and 100 mL 
- Volumetric pipettes. Class A, 5, 10 mL 
- Graduated pipettes, 5, 10 mL 
- Graduated cylinders, 25, 100 and 1000 mL 
- Round-bottomed inactinic glass tubes, 25 mL 
- Conical-bottomed inactinic glass tubes, 10 mL 
-     Autosampler vials in inactinic glass  
 
2.1.2 Small equipment 
 
- Pipettes, Gilson, P200 and P1000 
- Pipette, Eppendorf 10-100 µL 
- Pipette, Biohit, Proline 5-50 µL 
- Pipettes, Biohit e-pet,  50-1200 µL 
- Pipettes, Biohit e-pet,  200-5000 µL 
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- Ultrasonic bath 
- Vortex mixer 
- Hot-block evaporator 
- Filters, Millipore HV, 0.45 μm 
- pH paper 5.0 – 10.0 
- Hot-bloc magnetic agitator  
 
2.2 Instrumentation 
 
- Reciprocating agitator  
- Milli Q, Millipore for ultra pure water  
- Scale, Mettler, Hospitalet de Llobregat, Spain 
- Refrigerated centrifuge 
- Freezer (-75°C)  
- pH-meter 
- Vacuum pump, Millipore, Billerica, MA, USA and Edwards,  Tewksbury, MA, USA 
- Fridge, Liebherr 
- Solvent delivery pump, Waters, Milford, MA, USA 
- Refrigerated autosampler, Waters, Milford, MA, USA 
- Column oven, Waters, Milford, MA, USA 
- Temperature Controle Module, Waters, Milford, MA, USA 
- Fluorimetric detector, Waters, Milford, MA, USA 
- Data acquisition software, Waters, Milford, MA, USA 
 
 
III. CHROMATOGRAPHIC CONDITIONS  
 
 Chromatographic mode: reversed-phase chromatography with C18 column 
 Guard and analytical columns:  
  Guard: Merck lichrospher100 RP18e, 4x4 mm, 5 µm. 
Analytical : Merck lichrospher100 RP18e (250x4) mm, 5 µm 
 Column temperature: 35 °C 
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 Elution : gradient 
 Mobile phase : 
 
 
Time (min) Mobile phase A (%) Mobile phase B(%) 
0 100 0 
16 100 0 
17 75 25 
22 75 25 
23 100 0 
30 100 0 
 
 Flow rate : 1 mL/min 
 Injection volume: 50 µL except for calibration point at 5.0µg/g: 20µL. 
 Autosampler temperature: About 10 °C 
 Detection: fluorimetric  Wavelengths: λexcitation: 295 nm for excitation 
        λemission: 500 nm for emission 
 Retention time :  about 9 to 12 min. for marbofloxacin 
            about 13 à 15 min. for ofloxacin 
 Run time : 30 minutes 
 Weighting factor: 1/C2 (Calculation performed with the heights of the peaks) 
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Chromatogramm of a standard solution at 1 µg/mL in mobile phase 
 
 
IV. CALIBRATION SAMPLES 
 
 
All the calibration samples from 0 to 5.0 µg/g were processed as described in the tonsil 
marbofloxacin extraction. 50 µL of solution IS2 were added to each calibration point sample, 
except for the blank porcine tonsil (ge0). 
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